BARD1 Life Sciences (ASX:BD1) share price jumps on cancer test update

The quest for BARD1's ELISA test takes another step forward.

| More on:
man jumping along increasing bar graph signifying jump in alumina share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The BARD1 Life Sciences Ltd (ASX: BD1) share price has walked through today's session in the green.

Before the open, BARD1 updated investors on a significant milestone in the development of its ELISA diagnostics test.

Let's investigate further.

A quick recap on BARD1 Life Sciences

BARD1 is a clinical diagnostics business with a focus on developing detection tests in a range of various cancers.

In addition, BARD1 also has a heavy interest in the research and development of non-invasive diagnostic tests for the early detection of cancer.

At the time of writing, BARD1 has a market capitalisation of $128 million.

What did BARD1 announce?

The company announced it had achieved proof of concept for its enzyme-linked immunosorbent assay (ELISA) based test for ovarian cancer.

BARD1's research partner at Griffith University showed how an initial ELISA test can detect a key biomarker found in tumour cells "from stages I–IV ovarian cancer".

Moreover, the ELISA test demonstrated it could detect the biomarker with "100% sensitivity and specificity" compared to the control group.

This is important because the test needs to "do what it says on the tin". That's to distinguish the biomarker in cases of ovarian cancer, not in "healthy controls" as BARD1 puts it.

As a result, it seems the outcome is a win for the ELISA regime, described as a "low-cost assay that can be performed in commercial laboratories worldwide", as per the release.

Moving forward, Griffith University and BARD1 will now "advance to the optimisation phase" for the ELISA test.

What did management say?

Referencing the data, BARD1 chief scientific officer, Dr Peter French said:

These data represent a key go decision to progress the optimisation and validation of our SubB2M ELISA-based tests that are expected to improve existing cancer biomarker tests for ovarian, breast, prostate and other cancers.

BARD1 Life Sciences share price snapshot

The BARD1 Life Sciences share price has climbed 114% into the green this year to date, extending the gain over the previous 12 months by 62%.

These results have outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of around 25% over the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A business woman looks unhappy while she flies a red flag at her laptop.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

a man in a business suit sits at his laptop computer at his desk and smiles broadly in an office setting, giving an air of optimism and confidence.
Opinions

This ASX 200 share has made the most money for my portfolio. I'm expecting a lot more

There’s one key reason why I’m expecting strong growth from this stock.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Share Market News

These ASX 200 stocks doubled in FY25. Can they do it again in FY26?

Let's find out.

Read more »

Woman on her phone with diagrams of tech sector related elements linking with each other.
Share Market News

Which magnificent 7 stock would I buy today with $5,000?

One stands above the rest.

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Share Market News

5 things to watch on the ASX 200 on Monday

It looks set to be a decent start to the week for Aussie investors.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

These ASX 200 shares could rise 30% to 50%

Brokers have good things to say about these cheap shares.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Share Market News

Record CBA share price and Iran-Israel ceasefire lift ASX 200 financials to new peak

ASX financial shares led the 11 market sectors last week, gaining 1.82% and reaching a record high.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »